Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock

What Was Tested

In this not phased trial, researchers set out to test BNP (Nesiritide).

Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis.

It had 1 arm (groups): rh-BNP arm (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 30 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age \>18 years. Fulfilling the Sepsis-3 definition of septic shock at initial stage. Hemodynamic stability achieved after adequate initial resuscitation and individualized hemodynamic optimization. Adequate perfusion with warm extremities, and capillary refill time \<3 seconds. Ongoing pulse index continuous cardiac output (PiCCO) hemodynamic monitoring and sinus rhythm.

The full record lists 12 inclusion and 10 exclusion criteria; among the exclusions: pregnancy or lactation; trauma or neurological diseases (including intracerebral hemorrhage and cerebral infarction); pre-existing severe heart failure (new york heart association \[nyha\] class iii-iv) or acute myocardial infarction within the past 30 days.

How the Study Was Run

The set-up was single-group and open-label.

Everyone knew when BNP (Nesiritide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-12 with completion listed for 2026-06.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): The pressure gradient of venous return (time frame: From baseline to 30 minutes after rh-BNP initiation).

It also tracked 7 secondary outcomes, for example Perfusion pressure, CVP, GEDI and global and left-ventricular preload (LVEDV), Renal microvascular resistance, Lactate clearance and Duration of invasive mechanical ventilation.

What This Means in Plain Language

Put simply, this is a not phased trial of BNP (Nesiritide) in 30 people.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the BNP (Nesiritide) compound page, all human trials.